Pci Bioscience Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 28-12-2024
- Paid Up Capital ₹ 0.10 M
as on 28-12-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.70 M
as on 28-12-2024
- Revenue -27.34%
(FY 2022)
- Profit 530.51%
(FY 2022)
- Ebitda -53.16%
(FY 2022)
- Net Worth 113.10%
(FY 2022)
- Total Assets -5.79%
(FY 2022)
About Pci Bioscience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.70 M.
Bishamber Goyal and Ravi Goyal serve as directors at the Company.
- CIN/LLPIN
U24100HR2011PTC043514
- Company No.
043514
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Hisar, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Pci Bioscience Private Limited offer?
Pci Bioscience Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics, Ayurvedic, Herbal Oils and Cosmetics, Ayurvedic Cosmetics, Ayurvedic Pain Relief Oil, Digestive System Drugs & Medicines, Gastrointestinal Drugs, Ayurvedic Medicine, Cereals & Food Grains, Wheat.
Who are the key members and board of directors at Pci Bioscience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bishamber Goyal  | Director | 28-Jul-2011 | Current |
| Ravi Goyal | Director | 28-Jul-2011 | Current |
Financial Performance of Pci Bioscience.
Pci Bioscience Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 27.34% decrease. The company also saw a substantial improvement in profitability, with a 530.51% increase in profit. The company's net worth Soared by an impressive increase of 113.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pci Bioscience?
In 2022, Pci Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 09 Jun 2020 | ₹0.25 M | Open |
Uco Bank Creation Date: 30 Oct 2015 | ₹1.45 M | Open |
How Many Employees Work at Pci Bioscience?
Unlock and access historical data on people associated with Pci Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pci Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pci Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
